NCT06353529 2026-03-12
POPPY
Hamilton Health Sciences Corporation
Phase 4 Recruiting
Clinical Trials
12 trialsNCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT04042753 2025-08-08
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03636568 2024-07-23
DHAPS
Washington University School of Medicine
Phase NA Completed
NCT02419664 2022-03-31
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Göteborg University
Phase 3 Terminated
NCT02357498 2019-11-25
TRANSSPHER
St. Joseph's Hospital and Medical Center, Phoenix
Phase NA Completed
NCT00054756 2018-08-08
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02084134 2018-04-11
Steroid
Washington University School of Medicine
Phase NA Completed
NCT02549768 2016-10-12
Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery
Pontificia Universidad Catolica de Chile
Phase 4 Unknown
NCT00936741 2014-04-02
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Corcept Therapeutics
Phase 3 Completed
NCT01371565 2014-03-18
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Corcept Therapeutics
Phase 3 Completed
NCT00569582 2013-08-22
SEISMIC
Corcept Therapeutics
Phase 3 Completed